Sandoz Publishes Nine-Month 2026 Sales Update Presentation

Bitget2026/10/28 06:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sandoz reported a 40-asset biosimilar pipeline in its nine-month 2026 sales update.
Biosimilar pertuzumab reached regulatory submission in the European Union.
Pyzchiva held the leading biosimilar position across major European markets; global biosimilar penetration reached 54%.
Hyrimoz continued gaining European market share, supported by strong volume momentum.
Afqlir launched across 22 European markets, becoming a key contributor to regional growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sandoz Publishes Nine-Month 2026 Sales Update Presentation

You may also like

Crypto prices